Patents by Inventor Benjamin Eithan Reubinoff

Benjamin Eithan Reubinoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220233477
    Abstract: A method of generating human mature oligodendrocytes is disclosed. The method comprises contacting a cell population which comprises human pre-oligodendrocytes with an inhibitor of the MAPK/ERK pathway under conditions that allow the pre-oligodendrocytes to differentiate into mature oligodendrocytes. Use of the MAPK/ERK pathway inhibitor for treating diseases is also disclosed.
    Type: Application
    Filed: June 11, 2020
    Publication date: July 28, 2022
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventors: Benjamin Eithan REUBINOFF, Etti BEN-SHUSHAN
  • Publication number: 20220213445
    Abstract: A culture of human pluripotent stem cells (hPSCs) is disclosed. In the culture, more than 50% of the hPSCs are formative hPSCs and are capable of renewing. Uses thereof are also disclosed.
    Type: Application
    Filed: May 22, 2020
    Publication date: July 7, 2022
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventors: Benjamin Eithan REUBINOFF, Michal GROPP
  • Publication number: 20220098551
    Abstract: A method of generating retinal pigment epithelial (RPE) cells is disclosed. The method comprises: (a) culturing human pluripotent stem cells in a human feeder cell-conditioned medium to obtain a cultured population of human pluripotent stem cells; (b) culturing said cultured population of human pluripotent stem cells in a medium comprising a differentiating agent to obtain differentiating cells; and (c) culturing said differentiating cells in a medium comprising one or more members of the TGF? superfamily.
    Type: Application
    Filed: December 10, 2021
    Publication date: March 31, 2022
    Inventors: Benjamin Eithan REUBINOFF, Orna SINGER
  • Patent number: 11261433
    Abstract: An article of manufacture is disclosed which comprises at least two populations of autosomal-identical induced pluripotent stem cells (iPSCs), wherein the complement of sex chromosomes of the first population of the at least two populations is non-identical to the complement of sex chromosomes of the second population of the at least two populations. Uses thereof and methods of generating same are also disclosed.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: March 1, 2022
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Ithai Waldhorn, Benjamin Eithan Reubinoff
  • Patent number: 11230696
    Abstract: A method of generating retinal pigment epithelial (RPE) cells is disclosed. The method comprises: (a) culturing human pluripotent stem cells in a human feeder cell-conditioned medium to obtain a cultured population of human pluripotent stem cells; (b) culturing said cultured population of human pluripotent stem cells in a medium comprising a differentiating agent to obtain differentiating cells; and (c) culturing said differentiating cells in a medium comprising one or more members of the TGF? superfamily.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: January 25, 2022
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Benjamin Eithan Reubinoff, Orna Singer
  • Patent number: 11035857
    Abstract: A method of selecting retinal pigmented epithelial (RPE) cells from a mixed population of cells is disclosed. The method comprises: (a) analyzing the cells of the mixed population of cells for at least one of the following parameters: (i) cells which autofluorescence above a predetermined threshold; (ii) cells which express CD81 above a predetermined threshold; and (iii) cells which scatter light perpendicular to a laser beam above a predetermined threshold; and (b) selecting cells which are positive for at least one of the parameters, thereby sorting RPE cells from a mixed population of cells.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: June 15, 2021
    Assignees: Hadasit Medical Research Services and Development Ltd., Cell Cure Neurosciences Ltd.
    Inventors: Benjamin Eithan Reubinoff, Nurit Yachimovich-Cohen, Limor Matzrafi
  • Patent number: 10760049
    Abstract: The present invention relates to the generation of neural cells from undifferentiated human embryonic stem cells. In particular it relates to directing the differentiation of human ES cells into neural progenitors and neural cells and the production of functioning neural cells and/or neural cells of a specific type. The invention also includes the use of these cells for the treatment of neurological conditions such as Parkinson's disease.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: September 1, 2020
    Assignee: ES Cell International PTE Ltd.
    Inventor: Benjamin Eithan Reubinoff
  • Publication number: 20190225943
    Abstract: An article of manufacture is disclosed which comprises at least two populations of autosomal-identical induced pluripotent stem cells (iPSCs), wherein the complement of sex chromosomes of the first population of the at least two populations is non-identical to the complement of sex chromosomes of the second population of the at least two populations. Uses thereof and methods of generating same are also disclosed.
    Type: Application
    Filed: January 31, 2017
    Publication date: July 25, 2019
    Inventors: Ithai WALDHORN, Benjamin Eithan REUBINOFF
  • Publication number: 20190137482
    Abstract: A method of determining whether an agent is a neuroeffector is disclosed. The method comprises: (a) labeling dopaminergic neurons which are comprised in a mixed population of cells with a fluorescent dopamine analog; (b) measuring a level of fluorescence in the mixed population of cells; (c) exposing the mixed population of cells to the agent; (d) remeasuring a level of fluorescence in the mixed population of cells, wherein a change in the level of fluorescence is indicative of the substance being a neuroeffector.
    Type: Application
    Filed: January 8, 2019
    Publication date: May 9, 2019
    Applicants: Cell Cure Neurosciences Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Talya MORDECHAI DANIEL, Ofer WISER, Benjamin Eithan REUBINOFF
  • Publication number: 20180312805
    Abstract: A method of generating retinal pigment epithelium cells is disclosed. Cell populations comprising same and uses thereof are also disclosed.
    Type: Application
    Filed: October 26, 2016
    Publication date: November 1, 2018
    Applicants: CELL CURE NEUROSCIENCES LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Benjamin Eithan REUBINOFF, Orna SINGER, Osnat BOHANA-KASHTAN, Ofer WISER
  • Publication number: 20180216064
    Abstract: A method of generating retinal pigment epithelial (RPE) cells is disclosed. The method comprises: (a) culturing human pluripotent stem cells in a human feeder cell-conditioned medium to obtain a cultured population of human pluripotent stem cells; (b) culturing said cultured population of human pluripotent stem cells in a medium comprising a differentiating agent to obtain differentiating cells; and (c) culturing said differentiating cells in a medium comprising one or more members of the TGF? superfamily.
    Type: Application
    Filed: July 28, 2016
    Publication date: August 2, 2018
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventors: Benjamin Eithan REUBINOFF, Orna SINGER
  • Publication number: 20180008458
    Abstract: A method of treating a subject with dry-form age-related macular degeneration (AMD) is disclosed. The method comprises administering into the subretina of the subject a therapeutically effective amount of a pharmaceutical composition comprising human RPE cells, wherein at least 95% of the cells thereof co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), wherein the trans-epithelial electrical resistance of the cells is greater than 100 ohms to the subject, thereby treating the subject.
    Type: Application
    Filed: April 30, 2015
    Publication date: January 11, 2018
    Inventors: Eyal Banin, Benjamin Eithan Reubinoff, Osnat Bohana-Kashtan, Nir Netzer, Charles Sherard Irving
  • Publication number: 20170335278
    Abstract: The present invention relates to the generation of neural cells from undifferentiated human embryonic stem cells. In particular it relates to directing the differentiation of human ES cells into neural progenitors and neural cells and the production of functioning neural cells and/or neural cells of a specific type. The invention also includes the use of these cells for the treatment of neurological conditions such as Parkinson's disease.
    Type: Application
    Filed: May 15, 2017
    Publication date: November 23, 2017
    Applicant: ES Cell International PTE Ltd.
    Inventor: Benjamin Eithan REUBINOFF
  • Publication number: 20170199190
    Abstract: A method of selecting retinal pigmented epithelial (RPE) cells from a mixed population of cells is disclosed. The method comprises: (a) analyzing the cells of the mixed population of cells for at least one of the following parameters: (i) cells which autofluorescence above a predetermined threshold; (ii) cells which express CD81 above a predetermined threshold; and (iii) cells which scatter light perpendicular to a laser beam above a predetermined threshold; and (b) selecting cells which are positive for at least one of the parameters, thereby sorting RPE cells from a mixed population of cells.
    Type: Application
    Filed: March 28, 2017
    Publication date: July 13, 2017
    Applicants: Cell Cure Neurosciences Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Benjamin Eithan REUBINOFF, Nurit YACHIMOVICH-COHEN, Limor MATZRAFI
  • Patent number: 9658216
    Abstract: A method of selecting retinal pigmented epithelial (RPE) cells from a mixed population of cells is disclosed. The method comprises: (a) analyzing the cells of the mixed population of cells for at least one of the following parameters: (i) cells which autofluorescence above a predetermined threshold; (ii) cells which express CD81 above a predetermined threshold; and (iii) cells which scatter light perpendicular to a laser beam above a predetermined threshold; and (b) selecting cells which are positive for at least one of the parameters, thereby sorting RPE cells from a mixed population of cells.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: May 23, 2017
    Assignees: Cell Cure Neurosciences Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Benjamin Eithan Reubinoff, Nurit Yachimovich-Cohen, Limor Matzrafi
  • Patent number: 9650605
    Abstract: The present invention relates to the generation of neural cells from undifferentiated human embryonic stem cells. In particular it relates to directing the differentiation of human ES cells into neural progenitors and neural cells and the production of functioning neural cells and/or neural cells of a specific type. The invention also includes the use of these cells for the treatment of neurological conditions such as Parkinson's disease.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: May 16, 2017
    Assignee: ES Cell International PTE Ltd.
    Inventor: Benjamin Eithan Reubinoff
  • Publication number: 20150377864
    Abstract: A method of determining whether an agent is a neuroeffector is disclosed. The method comprises: (a) labeling dopaminergic neurons which are comprised in a mixed population of cells with a fluorescent dopamine analog; (b) measuring a level of fluorescence in the mixed population of cells; (c) exposing the mixed population of cells to the agent; (d) remeasuring a level of fluorescence in the mixed population of cells, wherein a change in the level of fluorescence is indicative of the substance being a neuroeffector.
    Type: Application
    Filed: February 12, 2014
    Publication date: December 31, 2015
    Inventors: Talya MORDECHAI DANIEL, Ofer WISER, Benjamin Eithan REUBINOFF
  • Publication number: 20150125506
    Abstract: The present invention concerns RPE cells obtainable by directed differentiation from stem cell, particularly, human stem cells. It has been specifically found that culturing stem cells in the presence of one or more member of the TGF? superfamily, such as Activin A) induced directed differentiation into mature and functional RPE cells. This was evidenced by the expression of markers specific to mature RPE cells, including MiTF-A, RPE65 or Bestrophin). In accordance with one particular embodiment, the cells are a priori cultured with nicotinamide (NA) which was found to augment the cells' response to the inductive effect of the one or more member of the TGF? superfamily. The invention also provides methods of performing the directed differentiation, as well as methods for use of the resulting RPE cells.
    Type: Application
    Filed: December 29, 2014
    Publication date: May 7, 2015
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Masha IDELSON, Ruslana ALPER-PINUS, Alex OBOLENSKY, Eyal BANIN, Benjamin Eithan REUBINOFF
  • Publication number: 20150118749
    Abstract: The present invention concerns RPE cells obtainable by directed differentiation from stem cell, particularly, human stem cells. It has been specifically found that culturing stem cells in the presence of one or more member of the TGF? superfamily, such as Activin A) induced directed differentiation into mature and functional RPE cells. This was evidenced by the expression of markers specific to mature RPE cells, including MiTF-A, RPE65 or Bestrophin). In accordance with one particular embodiment, the cells are a priori cultured with nicotinamide (NA) which was found to augment the cells' response to the inductive effect of the one or more member of the TGF? superfamily. The invention also provides methods of performing the directed differentiation, as well as methods for use of the resulting RPE cells.
    Type: Application
    Filed: December 29, 2014
    Publication date: April 30, 2015
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Masha IDELSON, Ruslana ALPER-PINUS, Alex OBOLENSKY, Eyal BANIN, Benjamin Eithan REUBINOFF
  • Publication number: 20150010922
    Abstract: A method of selecting retinal pigmented epithelial (RPE) cells from a mixed population of cells is disclosed. The method comprises: (a) analyzing the cells of the mixed population of cells for at least one of the following parameters: (i) cells which autofluorescence above a predetermined threshold; (ii) cells which express CD81 above a predetermined threshold; and (iii) cells which scatter light perpendicular to a laser beam above a predetermined threshold; and (b) selecting cells which are positive for at least one of the parameters, thereby sorting RPE cells from a mixed population of cells.
    Type: Application
    Filed: January 29, 2013
    Publication date: January 8, 2015
    Inventors: Benjamin Eithan Reubinoff, Nurit Yachimovich-Cohen, Limor Matzrafi